Rocket Pharmaceuticals, Inc. Common Stock(RCKT)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$2.73
52-Week Range
$2.40 – $5.45
YTD
-20.95%
IV Rank (30D)
34.82
Straddle Price
$0.55
P/C Vol Ratio
0.45
Market Cap
$0.3B
Fair Value
+42.2% vs price
Confidence: 28% Alpha Score: 0.73

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.53%
Beta vs SPY1.00
Cost of Equity (CAPM)10.03% (VRP-adj)
WACC9.69%
Volatility Risk Premium+119.7pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.2B
Return on Equity (TTM)-88.0%
Book / Price80.3% — banking bias active (P/B is primary)
Debt / Equity0.08
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$3.35 (Market Anchor value)
SMA 20 / Bollinger Mid$2.94
Bollinger Width / SMA20903.4% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: BMRN, CRSP, VCYT (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$3.91
Current Price
$2.75
Deviation
+42.2%
Forward-Return Rank LONG gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -3.4% -0.16 +0.56 59.7%
42d -2.0% +0.59 +0.93 71.2%
63d -2.2% +0.46 +0.87 70.5%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $5.72 24% median 2.7× · 3 peers
Peer P/S n/a 0% median 7.1× · 3 peers
Market Anchor (SMA50) $3.35 76% stability 63% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$0.3B

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan -6.72% 6
Feb +1.18% 6
Mar -14.07% 6
Apr -3.98% 6
May -10.48% 6
Jun -1.29% 6
Jul +3.94% 5
Aug -9.26% 5
Sep +2.54% 5
Oct +4.35% 5
Nov -2.97% 5
Dec +4.89% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $2.91
SMA 50: $3.34
SMA 200: $3.55
Current: $2.75
EMA 12: $2.81
EMA 26: $3.02
MACD: -0.2098 | Signal: -0.0048
BEARISH
ADX (14): 22.85
WEAK TREND
+DI: 16.88
−DI: 27.74
Momentum Oscillators
RSI (14): 36.50
NEUTRAL
Stoch %K: 22.33
Stoch %D: 17.73
Williams %R: -64.52
Volume & Volatility
BB Upper: $3.25
BB Lower: $2.57
NEUTRAL
OBV: -89,501,021
Vol SMA 20: 2,503,871
Vol ROC: 7.93%
ATR: $0.19
True Range: $0.17
HV 20: 50.9%
HV 30: 55.1%
HV 60: 72.2%

Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:45.029000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

Earnings History
8 of 8 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-05 After-Close 16.80% 1.30% 0.08x Within
2024-11-07 After-Close 32.17% 2.43% 0.08x Within
2025-02-27 After-Close 26.89% 3.74% 0.14x Within
2025-05-08 Pre-Market 22.57% 6.25% 0.28x Within
2025-08-07 After-Close 17.80% 7.44% 0.42x Within
2025-11-06 Pre-Market 36.14% 2.66% 0.07x Within
2026-02-26 After-Close 20.62% 10.44% 0.51x Within
2026-05-07 After-Close 101.50% 1.09% 0.01x Within
Options Activity
IV Rank (30D)
34.82
IV Rank (7D)
100
Avg IV
181.8%
Straddle (30D)
$0.55
Straddle (7D)
$0.30
P/C Volume
0.45
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
2.08
Correlation (SPY)
32.6%
0.11
Ann. Volatility
78.7%
SPY Volatility
12.3%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 111,462,153 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

196 filers98,458,395 shares$347.82M value88.33% of float
# Filer Shares Value % of Total % of Float Period
1 RTW INVESTMENTS, LP 17,687,772 $63.32M 18.21% 15.87% 2026-03-31
2 VANGUARD GROUP INC Custodian 8,544,423 $29.99M 8.62% 7.67% 2025-12-31
3 BlackRock, Inc. Custodian 7,834,795 $28.05M 8.06% 7.03% 2026-03-31
4 CITIGROUP INC Custodian 5,107,708 $18.29M 5.26% 4.58% 2026-03-31
5 STATE STREET CORP 4,485,989 $16.06M 4.62% 4.02% 2026-03-31
6 MORGAN STANLEY Custodian 3,941,377 $13.83M 3.98% 3.54% 2025-12-31
7 MAVERICK CAPITAL LTD 3,567,372 $12.77M 3.67% 3.20% 2026-03-31
8 Newtyn Management, LLC 3,165,900 $11.33M 3.26% 2.84% 2026-03-31
9 Nuveen, LLC Custodian 3,128,753 $11.20M 3.22% 2.81% 2026-03-31
10 MILLENNIUM MANAGEMENT LLC Custodian 3,118,124 $11.16M 3.21% 2.80% 2026-03-31
11 AQR CAPITAL MANAGEMENT LLC Custodian 3,069,930 $10.99M 3.16% 2.75% 2026-03-31
12 MARSHALL WACE, LLP Custodian 3,038,715 $10.88M 3.13% 2.73% 2026-03-31
13 GEODE CAPITAL MANAGEMENT, LLC Custodian 2,189,256 $7.84M 2.25% 1.96% 2026-03-31
14 D. E. Shaw & Co., Inc. Custodian 2,169,625 $7.77M 2.23% 1.95% 2026-03-31
15 Monaco Asset Management SAM 2,058,303 $7.37M 2.12% 1.85% 2026-03-31
16 GOLDMAN SACHS GROUP INC Custodian 1,721,116 $6.16M 1.77% 1.54% 2026-03-31
17 UBS Group AG Custodian 1,298,173 $4.65M 1.34% 1.16% 2026-03-31
18 TWO SIGMA INVESTMENTS, LP 1,097,623 $3.93M 1.13% 0.98% 2026-03-31
19 FEDERATED HERMES, INC. 1,023,747 $3.67M 1.05% 0.92% 2026-03-31
20 Point72 Asset Management, L.P. 1,012,126 $3.62M 1.04% 0.91% 2026-03-31
21 Opaleye Management Inc. 955,000 $3.35M 0.96% 0.86% 2025-12-31
22 JPMORGAN CHASE & CO Custodian 796,224 $2.74M 0.79% 0.71% 2026-03-31
23 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 724,392 $2.59M 0.75% 0.65% 2026-03-31
24 Prosight Management, LP 683,856 $2.45M 0.70% 0.61% 2026-03-31
25 Aberdeen Group plc 664,821 $2.38M 0.68% 0.60% 2026-03-31
5 filers$1.34M notional
# Filer Notional Value % of Total Period
1 GOLDMAN SACHS GROUP INC Custodian $501.20K 37.32% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $372.32K 27.72% 2026-03-31
3 CITADEL ADVISORS LLC Custodian $232.34K 17.30% 2026-03-31
4 WOLVERINE TRADING, LLC Custodian $159.08K 11.85% 2025-09-30
5 JANE STREET GROUP, LLC Custodian $78.04K 5.81% 2026-03-31
4 filers$560.10K notional
# Filer Notional Value % of Total Period
1 CITADEL ADVISORS LLC Custodian $240.93K 43.02% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $229.12K 40.91% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $45.11K 8.05% 2026-03-31
4 WOLVERINE TRADING, LLC Custodian $44.94K 8.02% 2025-09-30
Insider Activity
Latest: 2023-02-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2023-02-22 John Militello See Remarks Exer (M) +2,858 EDGAR
2023-02-22 Gaurav Shah CEO Sell (S) −12,194 $19.06 -$232.4K EDGAR
2023-02-22 Gaurav Shah CEO Exer (M) +31,440 EDGAR
2023-02-22 Jonathan David Schwartz See Remarks Exer (M) +8,574 EDGAR
2023-02-22 John Militello See Remarks Sell (S) −1,244 $19.06 -$23.7K EDGAR
2023-02-22 Kinnari Patel See Remarks Exer (M) +15,720 EDGAR
2023-02-22 Jonathan David Schwartz See Remarks Sell (S) −3,557 $19.06 -$67.8K EDGAR
2023-02-16 John Militello See Remarks Grant (A) +66,414 opt EDGAR
2023-02-16 Jonathan David Schwartz See Remarks Grant (A) +166,037 RSU EDGAR
2023-02-16 Kinnari Patel See Remarks Grant (A) +265,661 opt EDGAR
2023-02-16 Martin Wilson General Counsel Grant (A) +116,226 RSU EDGAR
2023-02-16 Gaurav Shah CEO Grant (A) +464,907 RSU EDGAR
2022-12-23 RODERICK WONG Director Other (J) +2 RSU EDGAR
2022-12-22 RTW INVESTMENTS, LP Director Other (J) +2 RSU EDGAR
2022-10-11 RODERICK WONG Director Buy (P) +2,711,864 $14.75 $40.00M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
9 insiders · @ $2.75
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 RODERICK WONG Director 17,628,567 $48.48M -$32.05M 10 2022-12-23
2 Naveen Yalamanchi Director 16,272,635 $44.75M $28.86M 8 2022-06-15
3 RTW INVESTMENTS, LP Director 16,185,119 $44.51M $41.62M 5 2022-12-22
4 Gaurav Shah CEO 747,420 $2.06M -$1.14M 14 2023-02-22
5 Gotham Makker Director 674,901 $1.86M -$1.64M 7 2022-06-15
6 Kinnari Patel See Remarks 173,241 $476.4K -$856.2K 16 2023-02-22
7 DAVID P SOUTHWELL Director 95,160 $261.7K -$1.46M 7 2022-06-15
8 Jonathan David Schwartz See Remarks 94,546 $260.0K -$2.99M 13 2023-02-22
9 John Militello See Remarks 1,614 $4.4K -$23.7K 13 2023-02-22
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio1.2
EV/EBITDA-1.3
TTM Net Income$-0.2B
TTM EPS$-1.87
ROE-88.0%
Debt/Equity0.09